{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:26:02Z","timestamp":1790508362725,"version":"4.1.0"},"reference-count":24,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Exp Med"],"abstract":"<jats:p>N6-methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotic transcripts, and YTH structural domain family (YTHDF) 2 is a principal m6A reader that governs RNA stability and turnover. Accumulating evidence indicates that YTHDF2 exerts context-dependent and sometimes opposing functions across major neurological disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease, glioblastoma, epilepsy, and experimentally induced cognitive and neuropsychiatric conditions. By selectively promoting decay of m6A-marked transcripts - such as leucine rich repeat and immunoglobulin domain containing 2, axis inhibition protein 1, breast cancer type 1 susceptibility protein associated protein 1, mitogen-activated protein kinase kinase 4, family with sequence similarity 134 member B, and NOD-like receptor family pyrin domain-containing 3 - YTHDF2 modulates diverse processes including amyloid processing, Wnt signaling, ferroptosis, neuroinflammation, metabolic homeostasis, and autophagy. Its activity is further shaped by upstream regulatory pathways (e.g. , epidermal growth factor receptor-SRC proto-oncogene, non-receptor tyrosine kinase-extracellular signal-regulated kinase and protein arginine methyltransferase 6-cyclin-dependent kinase 9) and by dynamic interplay with m6A writers and erasers, including methyltransferase like 14 and fat mass and obesity-associated protein. This mini-review synthesizes recent mechanistic advances, emphasizes regional and cell-type heterogeneity of YTHDF2 function, and proposes a \u201cdose-target dependency\u201d framework to reconcile its bidirectional effects. We also outline emerging translational strategies aimed at evaluating YTHDF2 as a mechanistic biomarker and a selectively tractable therapeutic target in neurological disease.<\/jats:p>","DOI":"10.5493\/wjem.v16.i1.116383","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:30:26Z","timestamp":1773462626000},"source":"Crossref","is-referenced-by-count":2,"title":["Double-edged role of N6-methyladenosine reader YTH structural domain family protein 2 in neurological disorders: Molecular mechanisms and translational prospects"],"prefix":"10.5493","volume":"16","author":[{"given":"Yu-Meng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110619"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2024.2399914"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20379-7"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-024-01522-9"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01807-0"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03038-3"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116576"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00620"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-00880-2"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110235"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-023-03409-5"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-02984-4"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrn983"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03763-z"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102636"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15882"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.15586\/codon.glioblastoma.2017.ch8"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204104"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1974"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-020-00814-5"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/syn.22270"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103026"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.06.652480"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.12.019"}],"container-title":["World Journal of Experimental Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-315X\/full\/v16\/i1\/116383.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2220-315X\/full\/v16\/i1\/116383.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:32:18Z","timestamp":1773462738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-315X\/full\/v16\/i1\/116383.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":24,"journal-issue":{"issue":"1"},"alternative-id":["116383"],"URL":"https:\/\/doi.org\/10.5493\/wjem.v16.i1.116383","relation":{},"ISSN":["2220-315X"],"issn-type":[{"value":"2220-315X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}